New · CUSIP 929033207 · who reports it, how much, and how much it matters to them
21 of the 720 hedge fund managers we track reported shares of Vor Biopharma Inc. (Nasdaq: VOR) on Form 13F for 30 June 2026. Between them they reported USD 142m. The largest position belongs to Ra Capital Management, at USD 44m. The manager with the most riding on it is Great Point Partners, where it is 5.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 44m | 0.4% |
| 2 | Great Point Partners2 funds on PPLI.com | USD 31m | 5.9% |
| 3 | Logos Global Management1 fund on PPLI.com | USD 12m | 0.5% |
| 4 | Braidwell12 funds on PPLI.com | USD 11m | 0.4% |
| 5 | Boothbay Fund Management2 funds on PPLI.com | USD 10m | 0.1% |
| 6 | Millennium Management6 funds on PPLI.com | USD 7.9m | 0.0% |
| 7 | Sphera Funds Management1 fund on PPLI.com | USD 7.7m | 1.0% |
| 8 | Clearline Capital2 funds on PPLI.com | USD 5.3m | 0.3% |
| 9 | Citadel Advisors32 funds on PPLI.com | USD 3m | 0.0% |
| 10 | Eversept Partners3 funds on PPLI.com | USD 2.8m | 0.1% |
| 11 | Marshall Wace LLP84 funds on PPLI.com | USD 1.8m | 0.0% |
| 12 | D. E. Shaw & Co.15 funds on PPLI.com | USD 1m | 0.0% |
| 13 | Walleye Capital8 funds on PPLI.com | USD 858,000 | 0.0% |
| 14 | Two Sigma Investments35 funds on PPLI.com | USD 681,000 | 0.0% |
| 15 | Engineers Gate Manager1 fund on PPLI.com | USD 680,000 | 0.0% |
| 16 | Renaissance Technologies13 funds on PPLI.com | USD 608,000 | 0.0% |
| 17 | Sarissa Capital Management6 funds on PPLI.com | USD 468,000 | 0.3% |
| 18 | Squarepoint Ops7 funds on PPLI.com | USD 428,000 | 0.0% |
| 19 | Tudor Investment Corporation10 funds on PPLI.com | USD 361,000 | 0.0% |
| 20 | Scientech Research2 funds on PPLI.com | USD 347,000 | 0.3% |
| 21 | Entrypoint Capital1 fund on PPLI.com | USD 199,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Great Point Partners | USD 31m | 5.9% |
| 2 | Sphera Funds Management | USD 7.7m | 1.0% |
| 3 | Logos Global Management | USD 12m | 0.5% |
| 4 | Braidwell | USD 11m | 0.4% |
| 5 | Ra Capital Management | USD 44m | 0.4% |
| 6 | Clearline Capital | USD 5.3m | 0.3% |
| 7 | Scientech Research | USD 347,000 | 0.3% |
| 8 | Sarissa Capital Management | USD 468,000 | 0.3% |
| 9 | Eversept Partners | USD 2.8m | 0.1% |
| 10 | Boothbay Fund Management | USD 10m | 0.1% |
Vor Biopharma Inc. trades under the symbol VOR on the Nasdaq. Its CUSIP, the code used on Form 13F, is 929033207.
21 of the 720 hedge fund managers PPLI.com tracks reported Vor Biopharma Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 44m), Great Point Partners (USD 31m), Logos Global Management (USD 12m), Braidwell (USD 11m) and Boothbay Fund Management (USD 10m).
21 managers in our coverage reported it, and between them they run 244 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Great Point Partners, where the position was 5.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Vor Biopharma Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.